Trial Profile
A Post-Marketing Observational Surveillance Programme for Ambrisentan (VOLT)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Acronyms VOLT
- Sponsors GSK
- 16 Jun 2016 New trial record
- 06 May 2016 Results published in the Journal of Heart and Lung Transplantation